Yesterday, I wrote about four midterm races in which tort reform played a role. Unfortunately, in each case, the candidate supporting tort reform won the election. Incumbent US Senator and minority leader, Mitch McConnell (R-KY), defeated challenger Alison Grimes with 56% of the vote. The Republican party now controlling the Senate, Mr. McConnell is set
Midterm Elections 2014 in mind, here is a video from the New York Times delving into the mind of the undecided voter.
Today, the Huffington Post reported that important expansions of Medicaid hinge on several gubernatorial races across the country. About 5 million Americans are too poor to afford coverage under the Affordable Care Act, yet do not qualify for Medicaid. Huffington Post asserts that this gap is due to actions by the Supreme Court and Republican
In the 2014 midterm elections, campaign issues have ranged from immigration to healthcare, and from the military to education. Though it remained largely on the sidelines, tort reform remained a central issue for some candidates. Here, we will outline the role that tort reform has played in a few races this election cycle. First, the
A few weeks ago, the Center for American Progress published a short video detailing the deleterious effects tort reform has on public safety in Texas. Here’s what they had to say about their video: “A new video from Legal Progress, the legal policy program at the Center for American Progress, documents the damaging effects of
Last month, members of the US Congress sent letters to 14 generic drug manufacturers, demanding explanation for the recent, dramatic spike in the price of some 20 generic drugs. The Generic Pharmaceutical Association, a trade group representing the generic pharmaceutical industry, blames the increase on simple market forces, but many are suspicious of that response.
After several states passed tort reform legislation in 2004, the Economic Policy Institute published a report titled “The frivolous case for tort law change: Opponents of the legal system exaggerate its costs, ignore its benefits,” that revealed a number of important flaws in the argument for the necessity for and benefit from tort reform. Many
The recent approval of a drug for use in combating leukemia by the US Food and Drug Administration has shed light on the relatively controversial, albeit common practice by that organization of using surrogate markers of efficacy for determining the benefit of a given drug or therapy. Some believe this constitutes a low bar for
Tort reform has sullied the political landscape of this country for years. A set of proposed laws and regulations at both the state and federal level, one central aim of tort reform is to limit the compensation an injured party can recover in a personal injury lawsuit, or “tort,” attempting to “save” health care from
Because Eli Lilly, manufacturer of the psychiatric drug Cymbalta (duloxetine), has failed to provide adequate instruction as to properly taper the drug at discontinuation, thousands of patients across the country and around the world have faced serious withdrawal symptoms unnecessarily, prompting large numbers of Cymbalta withdrawal lawsuits. According to MedlinePlus, a medical encyclopedia curated by